|Articles|July 1, 2006

'Incidental to denials,' with managed care plans; same date of service charges

On an ongoing basis, our office receives denials from managed care plans stating that repair codes are bundled or "incidental to" the excision codes.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!

Related Content

Smartphone-Based Education Reduces Short-Term Relapse in Pediatric Atopic Dermatitis

ByMarie Bosslett, Assistant Editor

January 21st 2026

The Burden of the Atopic March: Real-World Data on Pediatric AD and Allergic Comorbidities in Japan

ByMarie Bosslett, Assistant Editor

January 20th 2026

Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types

ByKaitlyn Bader, Assistant Managing Editor

January 17th 2026

Dermatology Market Update 2026: Second Bites, Regulatory Headwinds, and the Flight Toward Scale

ByMichael Kroin, CEO, Physician Growth Partners

January 5th 2026

Dermatologists as Doctorpreneurs: Best Practices for Physician Side Hustles

ByDavid B. Mandell, JD, MBA

December 29th 2025

Latest CME

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Register now!

Multimedia

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

'Incidental to denials,' with managed care plans; same date of service charges

Newsletter

Related Content

Smartphone-Based Education Reduces Short-Term Relapse in Pediatric Atopic Dermatitis

The Burden of the Atopic March: Real-World Data on Pediatric AD and Allergic Comorbidities in Japan

Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types

Dermatology Market Update 2026: Second Bites, Regulatory Headwinds, and the Flight Toward Scale

Dermatologists as Doctorpreneurs: Best Practices for Physician Side Hustles

Latest CME

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Trending on Dermatology Times

AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review

Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis

FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA

Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older

Introducing Dermatology Times NP/PA Connect